Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study of LX-101 in pediatric population with IGF-1/IGF-1R enriched

Next Previous
Trial Profile

A study of LX-101 in pediatric population with IGF-1/IGF-1R enriched

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LX 101 (Primary)
  • Indications Cancer; Gastrointestinal stromal tumours; Rhabdomyosarcoma
  • Focus Adverse reactions

Most Recent Events

  • 27 Nov 2025 According to MR 9410686 and 9437314 company was planning more then 1 trial in pediatric and adult population in indications that carry strong ties to the IGF-1/IGF-1R pathway, including Ewing Sarcoma, DSRCT, rhabdomyosarcoma, and GIST, and according to MR 9452496 FDA have cleared the path to initiate a clinical trial in Ewing Sarcoma and DSRCT (in adolescent and young adult patients) hence created a separate profile (388039) for now please update once more info is available; removed Soft-tissue
  • 20 Mar 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top